

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Credit Suisse AG		01/31/2011	bank: SWITZERLAND
RECEIVING PARTY DATA			
Name:	Alpharma Pharmaceuticals LLC		
Street Address:	400 Crossings Blvd		
City:	Bridgewater		
State/Country:	NEW JERSEY		
Postal Code:	08807		
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE		
PROPERTY NUMBERS Total: 8			
Property Type	Number	Word Mark	
Serial Number:	77336776	OXSENAL	
Serial Number:	77333124	PAINPOINT	
Serial Number:	77333091	PAINPOINTS	
Serial Number:	77630899	PROCORE	
Registration Number:	3473263	PAINBALANCE	
Registration Number:	3473264	MAXIMIZE RELIEF. MINIMIZE ABUSE.	
Registration Number:	3738036	EMBEDA	
Registration Number:	3715908	EMBEDA	
CORRESPONDENCE DATA			
Fax Number:	(202)778-5299		
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>			
Phone:	202.662.5299		
Email:	trademarks@cov.com		
Correspondent Name:	Kathleen T. Gallagher-Duff		
Address Line 1:	1201 Pennsylvania Avenue, N.W.		

CH \$215.00 77336776

900182905

TRADEMARK
REEL: 004465 FRAME: 0652

Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

ATTORNEY DOCKET NUMBER: 029459.00030

NAME OF SUBMITTER: Cheryl L. Fountain/Paralegal Specialist

Signature: /cheryllfountain/

Date: 02/02/2011

Total Attachments: 3

source=Alpharma Pharmaceuticals LLC TM Release#page1.tif

source=Alpharma Pharmaceuticals LLC TM Release#page2.tif

source=Alpharma Pharmaceuticals LLC TM Release#page3.tif

Release of Security Interest in Trademarks

January 31, 2011

WHEREAS, KING PHARMACEUTICALS, INC., a Tennessee corporation, as Borrower, certain of its subsidiaries, as Guarantors, and CREDIT SUISSE AG (“**Credit Suisse**”), in its capacity as Collateral Agent for the Secured Parties (as each term is defined in the GCA (as defined below)), entered into that certain Guarantee and Collateral Agreement (the “**GCA**”) dated as of May 11, 2010;

WHEREAS, pursuant to the GCA, Credit Suisse and Alpharma Pharmaceuticals LLC, a Delaware limited liability company (the “**Assignee**”), entered into that certain Trademark Security Agreement dated May 11, 2010 and recorded with the United States Patent and Trademark Office on May 12, 2010 on Reel No. 4204, Frame No. 0879 (the “**Trademark Security Agreement**”);

WHEREAS, under the Trademark Security Agreement, the Assignee granted to Credit Suisse a security interest in certain Trademark Collateral (as defined in the Trademark Security Agreement), including those items set forth on Schedule 1 hereto (collectively, the “**Released Trademark Collateral**”);

WHEREAS, the parties agree and acknowledge that the foregoing United States Patent and Trademark Office assignment record may list Credit Suisse AG in a capacity other than Collateral Agent, and that the security interest was granted to, and this release is correctly made by, Credit Suisse, as Collateral Agent; and


WHEREAS, Credit Suisse desires to release the security interest granted by the Assignee under the Trademark Security Agreement in the Released Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Credit Suisse, as Collateral Agent for the Secured Parties, does hereby unconditionally, irrevocably and absolutely terminate, release, extinguish and forever discharge the security interest granted under the Trademark Security Agreement in the Released Trademark Collateral, together with all of the goodwill of the business connected with the use of, or symbolized by, such Released Trademark Collateral, and hereby unconditionally, irrevocably and absolutely assigns, transfers and conveys to the Assignee all right, title and interest of Credit Suisse in, to and under such Released Trademark Collateral and such goodwill granted under the Trademark Security Agreement. This Release of Security Interest in Trademarks shall be binding upon Credit Suisse’s legal representatives, assigns and successors, and upon the Secured Parties and their legal representatives, assigns and successors. Credit Suisse also hereby authorizes, and requests, the Director of the United States Patent and Trademark Office or his delegate to record this Release of Security Interest in Trademarks against the Released Trademark Collateral.


[signature page to follow]

IN WITNESS WHEREOF, Credit Suisse has caused this Release of Security Interest in Trademarks to be duly executed by its officers thereunto duly authorized as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN
ISLANDS BRANCH

By: 

Name: DOREEN BARR
Title: DIRECTOR

By: 

Name: VIPUL DHADDA
Title: ASSOCIATE

[signature page – Alharma Pharmaceuticals LLC trademark release]

Schedule 1

ALPHARMA PHARMACEUTICALS LLC

U.S. TRADEMARK REGISTRATIONS

Trademark	Registration No.	Registration Date
EMBEDA	3,715,908	November 24, 2009
EMBEDA Logo	3,738,036	January 12, 2010
MAXIMIZE RELIEF, MINIMIZE ABUSE	3,473,264	July 22, 2008
PAINBALANCE	3,473,263	July 22, 2008

U.S. TRADEMARK APPLICATIONS

Trademark	Application No.	Application Date
OXSENAL	77336776	November 26, 2007
PAINPOINT	77333124	November 19, 2007
PAINPOINTS	77333091	November 19, 2007
PROCORE	77630899	December 11, 2008

TRADEMARK LICENSES

Name of Agreement	Parties Licensor/Licensee	Date of Agreement	Subject Matter
Exclusive License and Distribution Agreement	IBSA (Institut Biochimique SA) / Alpharma Pharmaceuticals LLC	August 16, 2007	Flector Patch
Exclusive License and Distribution Agreement	IBSA (Institut Biochimique SA) / Alpharma Pharmaceuticals LLC	August 16, 2007	Tirosint